Related Experiment Video
Updated: Jul 19, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Drug resistance in diffuse large B-cell lymphoma
1Center for Cancer Treatment, National Cancer Institute, Bethesda, MD.
Abstract:
Despite significant advances in the treatment of diffuse large B-cell lymphoma (DLBCL), drug resistance remains a major cause of treatment failure. Early strategies to improve outcome were mostly empiric or relied on classical mechanisms of drug resistance and were largely unsuccessful. More recent approaches have been aided by an understanding of the molecular pharmacology of drug action and tumor biology. Microarray profiling in particular has provided important insights into the complex biology of DLBCL and has led to a molecular taxonomy based on cell of origin and pathways of lymphomagenesis. It is now recognized that drug resistance is a complex and dynamic process related to cell cycle and apoptotic pathways, cellular differentiation, and the microenvironment. Drugs that target potential pathways of drug resistance, such as nuclear factor kappaB (NFkappaB), cyclin-dependent kinases (CDKs), and BCL-2 have entered clinical trials. However, the complexity of drug resistance requires that future clinical trials incorporate molecular translational endpoints to help identify the biologic basis of treatment failure.
Insights
Drug resistance in diffuse large B-cell lymphoma (DLBCL) hinders treatment success. Understanding molecular pathways and incorporating molecular endpoints in trials are crucial for overcoming resistance and improving patient outcomes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Diffuse large B-cell lymphoma (DLBCL) treatment faces challenges due to drug resistance, a significant cause of therapeutic failure.
- Early treatment strategies were largely unsuccessful, lacking a deep understanding of resistance mechanisms.
- Advances in molecular pharmacology and tumor biology have improved therapeutic approaches.
Purpose of the Study:
- To review the complexities of drug resistance in DLBCL.
- To highlight the role of molecular profiling in understanding DLBCL biology and resistance.
- To discuss novel therapeutic targets and the need for molecular endpoints in clinical trials.
Main Methods:
- Review of current literature on DLBCL drug resistance.
- Analysis of insights from microarray profiling and molecular taxonomy.
- Examination of emerging drug targets and clinical trial designs.
Main Results:
- Drug resistance in DLBCL is a complex, dynamic process influenced by cell cycle, apoptosis, differentiation, and the microenvironment.
- Molecular profiling has elucidated DLBCL subtypes and lymphomagenesis pathways, informing resistance mechanisms.
- Targeted therapies against pathways like NF-kappaB, CDKs, and BCL-2 are under investigation.
Conclusions:
- Understanding the molecular basis of DLBCL drug resistance is essential for developing effective treatments.
- Future clinical trials must integrate molecular translational endpoints to identify resistance mechanisms and guide therapy.
- Targeting specific molecular pathways offers promise for overcoming drug resistance in DLBCL.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...